8-(1,1-Dimethylethyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 8-(1,1-Dimethylethyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-one
• 英文别名: 8-tert-butyl-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one
• 化学式: C₁₆H₁₉NO₂
• 分子量: 257.332
• InChiKey: KRJDDJDDIVUGBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-(1,1-Dimethylethyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-one 、 3-(2-Chloroethyl)-3-(2-azabicyclo<3.2.2>nonane) hydrochloride 在 甲醇 作用下， 以gave the product (3.7 g), mp 312°-315° C.的产率得到3-[2-(3-Azabicyclo[3.2.2]non-3-yl)ethyl]-8-(1,1-dimethylethyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-one, dihydrochloride
  参考文献：
  名称：

  3-[2-(Azabicyclo)

  摘要：

  本发明公开了用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能3-[2-(杂环双环)乙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]吡啶-5-酮。本发明还公开了制备所述化合物的方法，包含它们的制药组合物以及使用所述制药组合物的方法。

  公开号：

  US04404138A1
• 作为产物：
  描述：

  3-叔丁基苯酚 、 4-氧代哌啶-3-羰酸甲酯 盐酸盐 在 乙酸乙酯 作用下， 以gave the product (14.7 g), mp 181°-186° C.的产率得到8-(1,1-Dimethylethyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-one
  参考文献：
  名称：

  3-[2-(Mono-and

  摘要：

  本发明揭示了用于治疗哺乳动物的支气管痉挛性疾病的抗胆碱能3-[2-(单烷基和双烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]-吡啶-5-酮。还揭示了制备所述化合物的方法，包含它们的制药组合物和使用所述制药组合物的方法。还揭示了制备本发明所需的未取代苯并吡喃-[3,4-c]吡啶-5-酮中间体的方法。

  公开号：

  US04382939A1

文献信息

• 3-(2-Mono-and dialkylamino)propyl(-1,2,3,4-tetrahydro-5H-(1) benzopyrano(3,4-c)pyridin-5-ones and derivatives thereof, a process for their production, and pharmaceutical compositions containing such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0087280A2

  公开（公告）日：1983-08-31

  Antichofinergic 3-[2-(mono- and dialkylamino)-propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-c]-pyridin-5-ones, useful for treating bronchospastic diseases in mammals, are disclosed. Also disclosed are processes for preparing the compounds, and pharmaceutical compositions containing them. The novel compounds have the following formula: where X is a lower alkyl radial, Y is hydrogen or a lower alkyl, and R', R2 and R3 are, separately, hydrogen atoms or substituents. A process for preparing the intermediate which is required to prepare the unsubstituted benzopyrano-[3,4-c]pyridin-5- ones of the present invention is also disclosed

  本发明公开了可用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能 3-[2-(单烷基和二烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃并[3,4-c]吡啶-5-酮。 还公开了制备这些化合物的工艺和含有这些化合物的药物组合物。 这些新型化合物具有下式：其中 X 是低级烷基径向，Y 是氢或低级烷基，R'、R2 和 R3 分别是氢原子或取代基。 还公开了制备本发明未取代苯并吡喃并[3,4-c]吡啶-5-酮所需的中间体的工艺
• Novel 3-(2-(azabicyclo) ethyl)1,2,3,4-tetrahydro-5H(1)benzopyrano(3,4-c)pyridin-5-ones, pharmaceutical compositions containing them and processes for their production
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0101162A2

  公开（公告）日：1984-02-22

  Anticholinergic 3-[2-(azabicyclo)ethyl)-1,2,3,4-tetra- hydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones, useful for treating broncho-spastic diseases in mammals, are disclosed. Also disclosed are methods for preparing such novel compounds, and pharmaceutical compositions containing them. The novel compounds have the formula I: wherein R1 is a hydrogen atom, an alkyl radical having from 1 to 6 carbon atoms, an alkoxy radical having from 1 to 6 carbon atoms, or a hydroxy, nitro, halo, amino or acylamino radical; R2 is a hydrogen atom, a hydroxy radical, an alkyl radical having from 1 to 6 carbon atoms, an alkoxy radical having from 1 to 6 carbon atoms or a phenyl radical; R3 is a hydrogen atom or an alkoxy radical having from 1 to 6 carbon atoms; or R1 and R2 taken together are -OCH20-; or R2 and R3 taken together are -CH=CH-CH=CH-; and or a pharmaceutically acceptable salt thereof, provided that R1 is not hydroxy when R2 is -OC2H5 and X is

  本发明公开了可用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能 3-[2-(氮杂双环)乙基)-1,2,3,4-四氢-5H-[1]苯并吡喃并[3,4-c]吡啶-5-酮。还公开了制备此类新型化合物的方法以及含有这些化合物的药物组合物。这些新型化合物具有式 I： 其中 R1 是氢原子、具有 1 至 6 个碳原子的烷基、具有 1 至 6 个碳原子的烷氧基或羟基、硝基、卤代、氨基或酰氨基；R2 是氢原子、羟基、具有 1 至 6 个碳原子的烷基、具有 1 至 6 个碳原子的烷氧基或苯基； R3 是氢原子或具有 1 至 6 个碳原子的烷氧基；或 R1 和 R2 合起来是-OCH20-；或 R2 和 R3 合起来是-CH=CH-CH=CH-；以及 或其药学上可接受的盐，条件是当 R2 是-OC2H5 时 R1 不是羟基，且 X 是
• US4382939A
  申请人：——

  公开号：US4382939A

  公开（公告）日：1983-05-10
• US4404138A
  申请人：——

  公开号：US4404138A

  公开（公告）日：1983-09-13
• 3-[2-(Mono-and
  申请人：Warner Lambert Company

  公开号：US04382939A1

  公开（公告）日：1983-05-10

  Anticholinergic 3-[2-(mono- and dialkylamino)-propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]-pyridin- 5-ones useful for treating bronchospastic diseases in mammals are disclosed. Also disclosed are methods for preparing said compounds, pharmaceutical compositions containing them and methods for using said pharmaceutical compositions. A method for preparing the intermediate which is required to prepare the unsubstituted benzopyrano-[3,4-c]pyridin-5-ones of the invention is also disclosed.

  翻译结果如下： 披露了用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能3-[2-(单和二烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]吡啶-5-酮。还披露了制备所述化合物的方法、包含它们的药物组合物以及使用所述药物组合物的方法。还披露了制备本发明所需的不取代苯并吡喃[3,4-c]吡啶-5-酮的中间体的方法。